Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Neovacs to present at two major Investor Conferences:


Posted on: 30 Aug 16

PARIS and BOSTON, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced CEO Miguel Sieler will present at the 18th Annual Rodman & Renshaw Global Investment Conference and Bio Europe 2016.

The Rodman & Renshaw Global Investment Conference, being held September 11-13 in New York, NY, will host over 265 public and private companies, and several thousand attendees. The conference will bring together a vast audience of financial and strategic investors with growth companies in the fields of healthcare, natural resources, technology, media and telecommunications, and cleantech. In addition to corporate presentations, the conference facilitates one-on-one meetings with members of the investment community.

Miguel Sieler, CEO of Neovacs, will present the company at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am ET at the New York Palace Hotel, on the fourth floor in the Louis Room.

Neovacs will also present at Bio Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world’s most important meetings for the biotech industry. This year the Bio Europe event will draw over 3,500 attendees from 60 countries, representing 1,800 companies. It will provide Neovacs with the opportunity to meet with a vast audience of financial and strategic investors, as well as potential high-level partners.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

GlobeNewswire
globenewswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.